Bovinos y porcinos: 2-5 mL
Tirzepatide is FDA-approved for type 2 diabetes (as Mounjaro) and for obesity (as Zepbound)
A doctor who ignores these signals and continues to prescribe or recommend BPC-157 is not just breaking the rules but potentially betraying patient trust
Overview BPC-157 (Body Protection Compound-157) is a powerful regenerative peptide known for its ability to accelerate healing, reduce inflammation, and support recovery across the entire body
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
